Price
No data yet.
Social Signal Score
Revenue
$1.97M+262.62%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael McCormick
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 38
- Beta
- 0.29
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -51.28
Financials
Revenue
$1.97M+262.6%Net Income
$-4.83MEBITDA
$-1.51MFree Cash Flow
$-3.18MEPS (diluted)
$-26.64Shares Outstanding (diluted)
181.2K+270772798.4%Operating Expenses
$4.67MCash & Debt
$3.92MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $8.27M | $-17.52M | $-25.39 |
| 2024 | $8.74M | $-11.16M | $-280.00 |
| 2023 | $8.86M | $-20.21M | $-12602.45 |
| 2022 | $8.54M | $-14.53M | $-102268.25 |
| 2021 | $7.92M | $-19.55M | $-350143.15 |
| 2020 | $7.44M | $-15.84M | $-709679.95 |
| 2019 | $5.51M | $-18.11M | $-14408863.70 |
| 2018 | $5.00M | $-17.03M | $-149030000.00 |
| 2017 | $3.55M | $-13.38M | $-156123333.45 |
| 2016 | $1.29M | $-15.79M | $-184240000.00 |
| 2015 | $59.0K | $-26.58M | $-452302823.35 |
| 2014 | $295.0K | $-25.59M | $-467845407.05 |
| 2013 | $59.0K | $-21.76M | $-403861859.80 |
| 2012 | $0.00 | $-14.06M | $-478624625.85 |
Valuation
NUWEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·7h ago·Neutral
Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins MINNEAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights continued progress under its financial efficiency strategy, including significant gross margin improvement, sustained product quality and supply performance, and further optimization of its cost structure.
View source ↗ - Newsglobenewswire.com·15d ago·Positive
Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical Agreement expands Nuwellis' pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution Agreement expands Nuwellis' pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution
View source ↗
Earnings
Wed, Nov 11(in 2 months)
Consensus estimate $-13.65 per share
Typical surprise -53.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-26.64 vs $-23.80miss
- Tue, May 12$-0.73 vs $-0.35miss
- Tue, Mar 10$-0.52 vs $-0.55beat
- Wed, Nov 12$19.58 vs $-602.70beat
- Thu, Aug 14$-21.35 vs $-6.62miss
- Tue, May 13$-10.14 vs $-6.61miss
Estimates and results for NUWE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NUWE officers and directors.
- Bought
- $662k
- Sold
- $74
15 trades
1 trade
- Jaramillo Nestor Jr.bought
- Erb John Lbought
- Erb John Lbought
- Erb John Lbought
- Waller Gregory Dsold
- Erb John Lbought
- Erb John Lbought
- Erb John Lbought
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.